Use of Ibandronate in Diabetic Patients

• Status: Completed
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to examine whether monthly oral administration of ibandronate to postmenopausal osteoporosis patients with type 2 diabetes differs in safety and efficacy compared to patients without diabetes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yeouido St. Mary's Hospital
• Collaborators: Samsung Medical Center; Seoul National University Bundang Hospital
• Treatments: Calcium Carbonate; Cholecalciferol; Ibandronic Acid

Criteria

Inclusion Criteria:

• age of at least 55 years at the time of screening

• postmenopausal woman

• diagnosis of osteoporosis

Exclusion Criteria:

• history of osteoporosis treatment

• underlying disease (e.g., heart failure, liver disease, renal disease, or malignancy)

• the use of drugs that affect bone metabolism (e.g., steroids, immunosuppressants, gonadotropin-releasing hormone agonists, aromatase inhibitors, thiazolidinedione drugs, anticonvulsants, and antidepressants)

• history of adverse effects of bisphosphonate or difficulty taking the drug due to an inability to sit or the presence of upper gastrointestinal disease